Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S1TI
|
|||
| Former ID |
DIB001916
|
|||
| Drug Name |
RX-5902
|
|||
| Synonyms |
Microtubule-cell cycle inhibitor (oral, cancer), Rexahn; Piperazine G2/M-specific cell cycle and Bcl inhibitors (oral,cancer), Rexahn
Click to Show/Hide
|
|||
| Indication | Triple negative breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-9: 140-199, 210-229] | Phase 1 | [2] | ||
| Company |
Rexahn
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H24FN5O4
|
|||
| Canonical SMILES |
COC1=CC(=CC(=C1)N2CCN(CC2)C(=O)NC3=NC4=C(C=CC(=C4)F)N=C3OC)OC
|
|||
| InChI |
1S/C22H24FN5O4/c1-30-16-11-15(12-17(13-16)31-2)27-6-8-28(9-7-27)22(29)26-20-21(32-3)25-18-5-4-14(23)10-19(18)24-20/h4-5,10-13H,6-9H2,1-3H3,(H,24,26,29)
|
|||
| InChIKey |
KAKPGJJRYRYSTP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 888478-45-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | ATP-dependent RNA helicase DDX5 (DDX5) | Target Info | Modulator | [3] |
| Phosphorylated p68 RNA helicase (pDDX5) | Target Info | Inhibitor | [1] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02003092) RX-5902 Treatment of Subjects With Solid Tumors. U.S. National Institutes of Health. | |||
| REF 3 | Company report (Rexahn) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.